Hematology

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

S. Vincent Rajkumar, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

EPCORE FL-1: Epcoritamab Plus Lenalidomide and Rituximab for Follicular Lymphoma

Gilles Salles, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

KOMET-001 Leads to Ziftomenib Approval for NPM1-Mutated AML

Eunice Wang, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD